Anthrax drug Anthim shown to be effective in rabbit and primate studies

The biopharmaceutical company Elusys Therapeutics, Inc., has announced positive results for its Anthim anthrax anti-toxin program.

The results of recent animal efficacy and human safety data, stemming from rabbit and primate studies as well as clinical safety studies, have highlighted the therapeutic potential for Anthim in the treatment of anthrax disease.

Up to 79 percent of animals treated by a single, intravenous dose of Anthim at the onset of symptoms as part of an established non-human primate treatment model survived a lethal inhalational challenge with anthrax spores.

A previously conducted rabbit treatment study showed that a single dose of Anthim provided a 94 percent survival rate when administered after the first symptoms of the disease were present.

The two studies' results are consistent with previously conducted rabbit and primate studies using Anthim and show the dramatic increase in survival rates attributable to Anthim.

In Elusys Therapeutics' dose-escalating human clinical safety study, preliminary results show that Anthim is both safe and well-tolerated at doses at or above the anticipated efficacious dose in humans.

"We are extremely pleased with the continued success of our Anthim program as we move into the final stages of drug development," Elizabeth Posillico, president and chief executive officer of Elusis, said. "Anthim consistently provides significant survival benefit in the treatment of anthrax infection and is safe and well-tolerated. Our drug has the potential to deliver considerable therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

The project was supported with federal funds from BARDA and the Department of Health and Human Services in conjunction with the National Institute of Allergy and Infectious Diseases, the National Institute of Health and the department of Health and Human Services.